WO2022098321A1 - Process for the preparation of sterilised suspensions for the administration by inhalation - Google Patents
Process for the preparation of sterilised suspensions for the administration by inhalation Download PDFInfo
- Publication number
- WO2022098321A1 WO2022098321A1 PCT/TR2020/051065 TR2020051065W WO2022098321A1 WO 2022098321 A1 WO2022098321 A1 WO 2022098321A1 TR 2020051065 W TR2020051065 W TR 2020051065W WO 2022098321 A1 WO2022098321 A1 WO 2022098321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucocorticosteroid
- process according
- suspension
- mixture
- inhalation
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 39
- 239000003862 glucocorticoid Substances 0.000 claims description 34
- 230000001954 sterilising effect Effects 0.000 claims description 16
- -1 cortivasole Chemical compound 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 11
- 229960000289 fluticasone propionate Drugs 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 229960002714 fluticasone Drugs 0.000 claims description 8
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 8
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 239000006172 buffering agent Substances 0.000 claims description 5
- 239000002270 dispersing agent Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000375 suspending agent Substances 0.000 claims description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 229960004544 cortisone Drugs 0.000 claims description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 4
- NBMKJKDGKREAPL-CXSFZGCWSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-CXSFZGCWSA-N 0.000 claims description 3
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims description 3
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims description 3
- 229960002478 aldosterone Drugs 0.000 claims description 3
- 229960004436 budesonide Drugs 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 3
- 229960003662 desonide Drugs 0.000 claims description 3
- 229960002593 desoximetasone Drugs 0.000 claims description 3
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims description 3
- 229960003654 desoxycortone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960004511 fludroxycortide Drugs 0.000 claims description 3
- 229960003469 flumetasone Drugs 0.000 claims description 3
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims description 3
- 229960000676 flunisolide Drugs 0.000 claims description 3
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims description 3
- 239000013029 homogenous suspension Substances 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229960001810 meprednisone Drugs 0.000 claims description 3
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- 229960001664 mometasone Drugs 0.000 claims description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 3
- 229960002858 paramethasone Drugs 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 238000002663 nebulization Methods 0.000 abstract description 3
- 230000000414 obstructive effect Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 15
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000003692 ilium Anatomy 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940125389 long-acting beta agonist Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- HJRDNARELSKHEF-CLFAGFIQSA-N 2-[2-[(z)-octadec-9-enoyl]oxyethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC\C=C/CCCCCCCC HJRDNARELSKHEF-CLFAGFIQSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical class C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical group CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940072958 tetrahydrofurfuryl oleate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the invention relates to a process for the preparation of a sterile suspension to be used in pharmaceutical formulations for inhalation by nebulization which is used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive respiratory diseases.
- COPD chronic obstructive pulmonary disease
- compositions for inhalation used in the treatment of obstructive respiratory diseases can comprise various active agents such as long acting muscarinic antagonists (LAMA), long acting beta agonists (LABA), short acting beta-2 agonists (SABA) and glucocorticosteroids.
- LAMA long acting muscarinic antagonists
- LABA long acting beta agonists
- SABA short acting beta-2 agonists
- glucocorticosteroids glucocorticosteroids
- Glucocorticosteroids are a class of drug that lowers inflammation in the body. Inhaled glucocorticosteroids reduce inflammation in the airways that carry air to the lungs (bronchial tubes) and reduce the mucus made by the bronchial tubes which makes easier to breathe.
- glucocorticosteroids such as ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynol
- Fluticasone is the most commonly used glucocorticosteroid for inhalation.
- Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, anti-inflammatory and antipruritic effects.
- Fluticasone propionate sold under the brand name Flixotide, is a steroid medication.
- Flixotide Fluticasone propionate, sold under the brand name Flixotide, is a steroid medication.
- bronchioli and alveoli one of the most important parameters that must be met by pharmaceutical formulations for inhalation is sterility.
- the droplet size of the nebulised formulation is an important parameter. Droplet size depends to some extent on the type of nebuliser used, whether a facemask or a mouthpiece is used and the pressure or flow rate of the compressed gas, as well as on the physical properties of the formulation for nebulisation.
- the nebulised formulation will be heterodisperse, i.e. droplets will cover a range of sizes.
- sterile pharmaceutical formulations for inhalation.
- the active ingredient can be sterilised by dry heating or irradiation, followed by preparation of the formulation under aseptic conditions, or the formulation can be pre-prepared and sterilised by treatment in an autoclave or by filtration.
- Irradiation based sterilization is known and has been recommended for glucocorticosteroids (see Ilium and Moeller in Arch. Pharm. Chemi. Sci., Ed. 2, 1974, pp. 167-174). However, significant degradation has been reported when irradiation has been used to sterilize micronized glucocorticosteroids. Sterilization by p or y-irradiation is also known. Indeed, Ilium and Moeller in Arch. Pharm. Chemi. Sci., Ed. 2,1974, pp. 167-174 recommend the use of irradiation to sterilize glucocorticosteroids. However, when such irradiation is used to sterilize certain finely divided, e.g., micronized steroids such as glucocorticosteroids, they are significantly degraded.
- WO 99/25359 relates to a process for sterilising corticosteroids by heating them at lower temperatures than those reported in some Pharmacopoeias (110-130°C vs 140-180°C) but does not contain any teaching as to how to prepare the relevant pharmaceutical formulations in the form of suspensions.
- WO 99/32156 relates to a sterilisation process for pharmaceutical suspensions.
- WO 95/31964 discloses suspension formulations suitable for nebulization, for administration by inhalation, comprising fluticasone propionate with a particle size less than 12 microns, one or more surfactants, one or more buffer agents and water.
- WO 051/15332 provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time.
- the main object of the present invention is to provide a production method for preparing sterile pharmaceutical glucocorticosteroid compositions for inhalation which eliminate all aforesaid problems and bring additional advantages to the relevant prior art.
- the main object of the present invention is to provide a production method for preparing sterile pharmaceutical glucocorticosteroid compositions for inhalation for use in the prevention, treatment, or in the alleviation of the symptoms of respiratory diseases, particularly asthma and chronic obstructive pulmonary disease.
- Another object of the present invention is to obtain sterile pharmaceutical glucocorticosteroid compositions for inhalation having high homogeneity and uniformity with an appropriate concentration of glucocorticosteroids.
- Another object of the present invention is to develop a process for preparing a suspension of glucocorticosteroids with enhanced uniformity and homogeneity.
- Another object of the present invention is to reduce processing times and obtain a sterile, homogeneous suspension of fluticasone or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a process for the sterilization of a glucocorticosteroid which process comprises heat treating of a suspension of fluticasone or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to produce a much lower level of total impurities than the prior art sterilization.
- the present invention relates to a process for the preparation of a sterile suspension to be used in pharmaceutical formulations for inhalation by nebulisation, which comprises the following steps:
- glucocorticosteroid suspension comprising a glucocorticosteroid, water and one or more pharmaceutically acceptable excipients
- - sterilising the homogenous suspension comprises the step of heating an aqueous suspension of glucocorticosteroid
- the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from 1 mg/ml to about 14 mg/ml.
- said process reduces processing times and gives rise to suspensions with a homogenous, thus producing compositions with a high level of physical stability and therapeutic efficacy.
- said process of sterilization comprises the step of heating an aqueous suspension of a glucocorticosteroid for a sterilizing-effective time.
- glucocorticosteroid or “glucocorticoid” refers to any of a group of steroid hormones (including derivatives, synthetic analogs, and pro-drugs), such as cortisone, which are produced by the adrenal cortex. These compounds are involved in carbohydrate, protein, and fat metabolism. Additionally, the glucocorticosteroids may have anti-inflammatory properties.
- said glucocorticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof
- suspensions obtained with the process according to the invention are used as pharmaceutical formulations for inhalation after being introduced into suitable containers for nebulisation.
- the concentration of active ingredient in the pharmaceutical formulations is 2 mg/2 mL and 0.5 mg/2 mL.
- suspensions may be prepared by conventional methods for the preparation of suspension formulations.
- the fluticasone propionate is contacted with the dispersing and/or suspending agents so as to "wet" it before addition to the bulk liquid containing the remaining excipients. Constant mixing is essential to maintain a homogeneous suspension.
- the bulk suspension is sterilised, conveniently by means of thermal sterilisation using steam.
- the dispersing or suspending agents used in the formulations of the present invention must be physiologically acceptable upon administration by inhalation.
- surfactants such as polysorbate 20, sorbitan monolaurate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetra hydrofurfuryl oleate, ethyl oleate, glyceryl mono-oleate, polyethylene glycol 400 and glyceryl monolaurate.
- the formulation according to the invention contains sorbitan monolaurate and polysorbate 20.
- suspensions are buffered to a pH of from about 5 to 7, preferably 6.
- Suitable buffering agents are those which are physiologically acceptable upon administration by inhalation.
- Such buffers include citric acid buffers and phosphate buffers, of which phosphate buffers are preferred.
- buffering agents for use in the formulations of the invention are monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous.
- suspensions will desirably be isotonic.
- the formulations may be adjusted to isotonicity by addition of a suitable isotonic agents, for example, sodium chloride.
- the formulations according to the invention additionally comprise sufficient sodium chloride, or another suitable pharmaceutically acceptable salt, to provide an isotonic composition.
- the present invention relates to a method of sterilizing active pharmaceutical ingredients, such as steroids that are susceptible to higher temperatures.
- the sterilization is preferably done at temperatures ranging from 100-140°C for 3-30 mins at varying pressures. Generally, the higher the temperature and pressure, the shorter the time required for adequate sterilization.
- the glucocorticosteroid is fluticasone, and the step of heating is by autoclaving at about 121°C for about 15 to about 30 minutes or at about 110°C for about 115 to about 150 minutes.
- the glucocorticosteroid is fluticasone propionate, and the step of heating is by autoclaving at about 121°C for about 15 to about 30 minutes or at about 110°C for about 115 to about 150 minutes.
- the glucocorticosteroid in yet other embodiments is at a concentration of from about 1 mg/ml to about 14 mg/ml.
- the present invention accordingly provides, in a first aspect, a formulation suitable for nebulisation comprising:
- the below given formulation can be used in the suspension subjected to the invention.
- Example 1 Example 2:
- glucocorticosteroid suspension comprising a glucocorticosteroid, water and one or more pharmaceutically acceptable excipients
- - sterilising the homogenous suspension comprises the step of heating an aqueous suspension of glucocorticosteroid
- the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from 1 mg/ml to about 14 mg/ml.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a process for the preparation of a sterile suspension to be used in pharmaceutical formulations for inhalation by nebulization which is used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive respiratory diseases.
Description
PROCESS FOR THE PREPARATION OF STERILISED SUSPENSIONS FOR THE ADMINISTRATION BY INHALATION
Field of Invention
The invention relates to a process for the preparation of a sterile suspension to be used in pharmaceutical formulations for inhalation by nebulization which is used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive respiratory diseases.
The background of the invention
Pharmaceutical compositions for inhalation used in the treatment of obstructive respiratory diseases can comprise various active agents such as long acting muscarinic antagonists (LAMA), long acting beta agonists (LABA), short acting beta-2 agonists (SABA) and glucocorticosteroids.
Glucocorticosteroids are a class of drug that lowers inflammation in the body. Inhaled glucocorticosteroids reduce inflammation in the airways that carry air to the lungs (bronchial tubes) and reduce the mucus made by the bronchial tubes which makes easier to breathe.
Among the various types of drug which are administered by inhalation for the treatment of the pulmonary diseases, glucocorticosteroids, such as ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof. They are generally administered in suspension, in an aqueous phase that usually also contains one or more pharmaceutically acceptable excipients, such as dispersing and/or suspending agents, isotonic and/or buffering agents, or in a propellant.
Fluticasone is the most commonly used glucocorticosteroid for inhalation. Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, anti-inflammatory and antipruritic effects. Fluticasone propionate, sold under the brand name Flixotide, is a steroid medication.
In order to ensure an effective and save penetration into the low respiratory tract of the patient, i.e. bronchioli and alveoli, one of the most important parameters that must be met by pharmaceutical formulations for inhalation is sterility. This requirement is becoming more and more mandatory as confirmed by the FDA final rule "Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation" published in the Federal Register of May 26, 2000 (65 FR 34082) governing the quality and safety of pharmaceutical products for a number of reasons, including the fact that the lungs are a particularly vulnerable organ of the human body, and many patients who use inhaled drugs have general health problems.
For introduction of the fluticasone propionate into the lungs, the droplet size of the nebulised formulation is an important parameter. Droplet size depends to some extent on the type of nebuliser used, whether a facemask or a mouthpiece is used and the pressure or flow rate of the compressed gas, as well as on the physical properties of the formulation for nebulisation. The nebulised formulation will be heterodisperse, i.e. droplets will cover a range of sizes.
The current trend is to produce inhalation formulations devoid of preservatives and bacteriostatics, as it has been reported in the literature that some of the substances commonly used for this purpose can induce allergic reactions or give rise to irritation of the respiratory mucosae (Menendez R et al J Allergy Clin Immunol 84, 272-274, 1989; Afferty P et al Thorax 43, 446-450, 1988).
Various processes can be used to manufacture sterile pharmaceutical formulations for inhalation. For example, the active ingredient can be sterilised by dry heating or irradiation, followed by preparation of the formulation under aseptic conditions, or the formulation can be pre-prepared and sterilised by treatment in an autoclave or by filtration.
Chemical sterilization, for the most part, has been based on exposure to toxic compounds, for example, ethylene oxide. However, when used to sterilize glucocorticosteroids, ethylene oxide has been found to leave residual amounts of ethylene oxide in the drug preparation. Ethylene oxide is toxic, and the residual levels are often above the pharmaceutically acceptable limits as set by most regulatory agencies.
Irradiation based sterilization is known and has been recommended for glucocorticosteroids (see Ilium and Moeller in Arch. Pharm. Chemi. Sci., Ed. 2, 1974, pp. 167-174). However, significant degradation has been reported when irradiation has been used to sterilize micronized glucocorticosteroids.
Sterilization by p or y-irradiation is also known. Indeed, Ilium and Moeller in Arch. Pharm. Chemi. Sci., Ed. 2,1974, pp. 167-174 recommend the use of irradiation to sterilize glucocorticosteroids. However, when such irradiation is used to sterilize certain finely divided, e.g., micronized steroids such as glucocorticosteroids, they are significantly degraded.
WO 99/25359 relates to a process for sterilising corticosteroids by heating them at lower temperatures than those reported in some Pharmacopoeias (110-130°C vs 140-180°C) but does not contain any teaching as to how to prepare the relevant pharmaceutical formulations in the form of suspensions.
In the patent application WO 00/25746, the applicant described a process for the preparation of aqueous suspensions for nebulisation based on a micronised active ingredient sterilised with gamma rays.
WO 99/32156 relates to a sterilisation process for pharmaceutical suspensions.
WO 95/31964 discloses suspension formulations suitable for nebulization, for administration by inhalation, comprising fluticasone propionate with a particle size less than 12 microns, one or more surfactants, one or more buffer agents and water.
WO 051/15332 provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time.
However, the state of art does not include any mention or motivation to reduce the duration of the homogenisation and mixing stage to obtain a homogeneous suspension.
Considering the state of art, there is still a need for innovative processes that will solve the homogeneity problem, and which will provide a standardized method for the fast production of stable inhalation compositions.
Objects and Brief Description of the Invention
The main object of the present invention is to provide a production method for preparing sterile pharmaceutical glucocorticosteroid compositions for inhalation which eliminate all aforesaid problems and bring additional advantages to the relevant prior art.
The main object of the present invention is to provide a production method for preparing sterile pharmaceutical glucocorticosteroid compositions for inhalation for use in the prevention, treatment, or in the alleviation of the symptoms of respiratory diseases, particularly asthma and chronic obstructive pulmonary disease.
Another object of the present invention is to obtain sterile pharmaceutical glucocorticosteroid compositions for inhalation having high homogeneity and uniformity with an appropriate concentration of glucocorticosteroids.
Another object of the present invention is to develop a process for preparing a suspension of glucocorticosteroids with enhanced uniformity and homogeneity.
Another object of the present invention is to reduce processing times and obtain a sterile, homogeneous suspension of fluticasone or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide a process for the sterilization of a glucocorticosteroid which process comprises heat treating of a suspension of fluticasone or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to produce a much lower level of total impurities than the prior art sterilization.
Detailed description of the invention
In accordance with the objects outlined above, detailed features of the present invention are given herein.
The present invention relates to a process for the preparation of a sterile suspension to be used in pharmaceutical formulations for inhalation by nebulisation, which comprises the following steps:
- preparing a mixture of a glucocorticosteroid suspension comprising a glucocorticosteroid, water and one or more pharmaceutically acceptable excipients,
- homogenizing the mixture in the aqueous suspension,
- sterilising the homogenous suspension comprises the step of heating an aqueous suspension of glucocorticosteroid,
- preparing the second mixture comprising water and one or more pharmaceutically acceptable excipients,
- filtrating the second final mixture,
- mixing the glucocorticosteroid suspension with the second filtered mixture, wherein the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from 1 mg/ml to about 14 mg/ml.
According to one embodiment, said process reduces processing times and gives rise to suspensions with a homogenous, thus producing compositions with a high level of physical stability and therapeutic efficacy.
According to one embodiment, said process of sterilization comprises the step of heating an aqueous suspension of a glucocorticosteroid for a sterilizing-effective time.
As used herein, "glucocorticosteroid" or "glucocorticoid" refers to any of a group of steroid hormones (including derivatives, synthetic analogs, and pro-drugs), such as cortisone, which are produced by the adrenal cortex. These compounds are involved in carbohydrate, protein, and fat metabolism. Additionally, the glucocorticosteroids may have anti-inflammatory properties.
In a preferred embodiment of the invention, said glucocorticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof
According to one embodiment, suspensions obtained with the process according to the invention are used as pharmaceutical formulations for inhalation after being introduced into suitable containers for nebulisation.
According to one embodiment, the concentration of active ingredient in the pharmaceutical formulations is 2 mg/2 mL and 0.5 mg/2 mL.
According to the preferred embodiment, suspensions may be prepared by conventional methods for the preparation of suspension formulations. Typically, the fluticasone propionate is contacted with the dispersing and/or suspending agents so as to "wet" it before addition to the bulk liquid containing the remaining excipients. Constant mixing is essential to maintain a
homogeneous suspension. The bulk suspension is sterilised, conveniently by means of thermal sterilisation using steam.
The dispersing or suspending agents used in the formulations of the present invention must be physiologically acceptable upon administration by inhalation. Within this category are included surfactants such as polysorbate 20, sorbitan monolaurate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetra hydrofurfuryl oleate, ethyl oleate, glyceryl mono-oleate, polyethylene glycol 400 and glyceryl monolaurate.
Preferably, the formulation according to the invention contains sorbitan monolaurate and polysorbate 20.
According to the preferred embodiment, suspensions are buffered to a pH of from about 5 to 7, preferably 6. Suitable buffering agents are those which are physiologically acceptable upon administration by inhalation. Such buffers include citric acid buffers and phosphate buffers, of which phosphate buffers are preferred.
Particularly preferred buffering agents for use in the formulations of the invention are monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous.
According to the preferred embodiment, suspensions will desirably be isotonic. The formulations may be adjusted to isotonicity by addition of a suitable isotonic agents, for example, sodium chloride.
Thus, in a preferred embodiment, the formulations according to the invention additionally comprise sufficient sodium chloride, or another suitable pharmaceutically acceptable salt, to provide an isotonic composition.
According to one embodiment, the present invention relates to a method of sterilizing active pharmaceutical ingredients, such as steroids that are susceptible to higher temperatures. The sterilization is preferably done at temperatures ranging from 100-140°C for 3-30 mins at varying pressures. Generally, the higher the temperature and pressure, the shorter the time required for adequate sterilization.
In an embodiment, the glucocorticosteroid is fluticasone, and the step of heating is by autoclaving at about 121°C for about 15 to about 30 minutes or at about 110°C for about 115 to about 150 minutes. Another embodiment contemplates that the glucocorticosteroid is fluticasone propionate, and the step of heating is by autoclaving at about 121°C for about 15 to about 30 minutes or at about 110°C for about 115 to about 150 minutes. The glucocorticosteroid in yet other embodiments is at a concentration of from about 1 mg/ml to about 14 mg/ml.
In a particularly preferred embodiment, the present invention accordingly provides, in a first aspect, a formulation suitable for nebulisation comprising:
- fluticasone propionate,
- polysorbate 20,
- sorbitan monolaurate,
- monosodium phosphate dihydrate,
- dibasic sodium phosphate anhydrous,
- sodium chloride,
- water for injection.
According to all these embodiments, the below given formulation can be used in the suspension subjected to the invention.
Example 1 :
Example 2:
The preparation method of the above-mentioned suspension given in example 1 is prepared by following these steps:
- preparing a mixture of a glucocorticosteroid suspension comprising a glucocorticosteroid, water and one or more pharmaceutically acceptable excipients,
- homogenizing the mixture in the aqueous suspension,
- sterilising the homogenous suspension comprises the step of heating an aqueous suspension of glucocorticosteroid,
- preparing the second mixture comprising water and one or more pharmaceutically acceptable excipients,
- filtrating the second final mixture,
- mixing the glucocorticosteroid suspension with the second filtered mixture, wherein the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from 1 mg/ml to about 14 mg/ml.
Claims
9
CLAIMS A process for the preparation of a sterile suspension to be used in pharmaceutical formulations for inhalation by nebulisation, which comprises the following steps:
- preparing a mixture of a glucocorticosteroid suspension comprising a glucocorticosteroid, water and one or more pharmaceutically acceptable excipients,
- homogenizing the mixture in the aqueous suspension,
- sterilising the homogenous suspension comprises the step of heating an aqueous suspension of glucocorticosteroid,
- preparing the second mixture comprising water and one or more pharmaceutically acceptable excipients,
- filtrating the second final mixture,
- mixing the glucocorticosteroid suspension with the second filtered mixture, wherein the concentration of the glucocorticosteroid in the glucocorticosteroid suspension is from 1 mg/ml to about 14 mg/ml. A process according to claim 1, wherein said the one or more pharmaceutically acceptable excipients are selected from dispersing, suspending, isotonic and/or buffering agents. A process according to claim 2, wherein the dispersing and/or suspending agent is selected from polysorbate 20 and/or sorbitan monolaurate. A process according to claim 2, wherein the isotonic agent is sodium chloride. A process according to claim 2, wherein the buffering agents are monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous. A process according to claim 1 , wherein the glucocorticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof.
A process according to claim 6, wherein the glucocorticosteroid is fluticasone propionate. A process according to claim 1 , wherein heating is carried out at a temperature of from 100°C to 140°C. A process according to claim 9, wherein heating is carried out by autoclaving. A process according to claim 9, wherein heating is carried out for 3 to 30 mins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/051065 WO2022098321A1 (en) | 2020-11-09 | 2020-11-09 | Process for the preparation of sterilised suspensions for the administration by inhalation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/051065 WO2022098321A1 (en) | 2020-11-09 | 2020-11-09 | Process for the preparation of sterilised suspensions for the administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022098321A1 true WO2022098321A1 (en) | 2022-05-12 |
Family
ID=81457330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2020/051065 WO2022098321A1 (en) | 2020-11-09 | 2020-11-09 | Process for the preparation of sterilised suspensions for the administration by inhalation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022098321A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050175546A1 (en) * | 2002-04-17 | 2005-08-11 | Barbara Sambuco | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
| WO2005115332A2 (en) * | 2004-05-17 | 2005-12-08 | Norton Healthcare, Ltd. | Heat sterilization of glucocorticosteroids |
| US20080269178A1 (en) * | 2004-11-16 | 2008-10-30 | John Miller | Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions |
-
2020
- 2020-11-09 WO PCT/TR2020/051065 patent/WO2022098321A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050175546A1 (en) * | 2002-04-17 | 2005-08-11 | Barbara Sambuco | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
| WO2005115332A2 (en) * | 2004-05-17 | 2005-12-08 | Norton Healthcare, Ltd. | Heat sterilization of glucocorticosteroids |
| US20080269178A1 (en) * | 2004-11-16 | 2008-10-30 | John Miller | Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4598268B2 (en) | New composition of matter | |
| US11052042B2 (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| ES2281197T3 (en) | PROCEDURE FOR PREPARATION OF PHARMACEUTICALLY ACCEPTABLE STERILE BECLOMETASONE DIPROPIONATE. | |
| AU710821B2 (en) | Fluticasone propionate formulations | |
| US7541021B2 (en) | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation | |
| EP2805712B1 (en) | Heat sterilization of glucocorticoidsteriods | |
| RU2611665C2 (en) | Improved composition of corticosteroid suspension for inhalation | |
| WO2022098321A1 (en) | Process for the preparation of sterilised suspensions for the administration by inhalation | |
| TR2023005107T2 (en) | METHOD FOR PREPARING STERILIZED SUSPENSIONS FOR USE BY INHALATION | |
| WO2022231533A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
| WO2022231531A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
| WO2022231532A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
| TR2023013885T2 (en) | METHOD OF PREPARING STERILIZED SUSPENSIONS FOR INHALATION BY NEBULIZATION | |
| TR2023013883T2 (en) | METHOD OF PREPARING STERILIZED SUSPENSIONS FOR INHALATION BY NEBULIZATION | |
| US20150290220A1 (en) | Pharmaceutical formualtions comprising a Gluococorticosteroid | |
| MXPA06006537A (en) | Aqueous suspensions of ciclesonide for nebulisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20960951 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20960951 Country of ref document: EP Kind code of ref document: A1 |